Imunon (FRA:CBO0) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CBO0 Imunon Inc FRA:CBO0
38 GF Score
Price €1.48
GF Value €5.35
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Imunon Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

FRA:CBO0
38GF Score
Imunon Inc FRA:CBO0
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Imunon (FRA:CBO0) Overvalued in 2026?

Based on GuruFocus' analysis, Imunon stock appears to be undervalued. The current stock price of €1.48 is trading 72.3% below its estimated GF Value™ of €5.35. GuruFocus considers Imunon to be Possible Value Trap.

Key valuation signals for FRA:CBO0:

  • Total Noninterest Expense:
  • GF Value™: €5.35 vs. price of €1.48 (72.3% below fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the FRA:CBO0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imunon Business Description

Other Exchanges IMNN:USACBO0:Germany
Address 997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
38GF Score

Get the complete analysis for FRA:CBO0

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.48
Price
€5.35
GF Value